Immunogenic formulation of OSPC antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens
US6486130B1 · kind B1 · utility
15Cited by
4References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 27, 1996 |
| Grant date | Nov 26, 2002 |
| Priority date | — |
| Expiry date | Jun 27, 2016 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A novel approach to Borrelia vaccine formulation taking into account serological, genotypic and epidemiological information by which OspC proteins from different strains of B burgdorferi are grouped together. OspC antigens are chosen in order to constitute a representative sample of such groupings, so that the resulting vaccine provides the greatest cross-protectivity with the fewest number of antigens.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.